VRDN
Income statement / Annual
Last year (2023), Viridian Therapeutics, Inc.'s total revenue was $314,000.00,
a decrease of 82.28% from the previous year.
In 2023, Viridian Therapeutics, Inc.'s net income was -$237.73 M.
See Viridian Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$314,000.00
|
$1.77 M
|
$2.96 M
|
$1.05 M
|
$4.46 M
|
$8.39 M
|
$4.00 M
|
$3.34 M
|
$2.54 M
|
$4.32 M
|
Cost of Revenue |
$1.32 M |
$755,000.00 |
$620,000.00 |
$28.30 M |
$32.79 M |
$30.42 M |
$19.62 M |
$2.55 M |
$2.47 M |
$3.24 M |
Gross Profit |
-$1.01 M |
$1.02 M |
$2.34 M |
-$27.25 M |
-$28.33 M |
-$22.04 M |
-$15.62 M |
$789,000.00 |
$66,000.00 |
$1.08 M |
Gross Profit Ratio |
-3.21 |
0.57 |
0.79 |
-25.96 |
-6.35 |
-2.63 |
-3.9 |
0.24 |
0.03 |
0.25 |
Research and Development
Expenses |
$159.77 M
|
$100.89 M
|
$56.89 M
|
$28.30 M
|
$34.79 M
|
$30.42 M
|
$19.62 M
|
$888,000.00
|
$1.00 M
|
$293,000.00
|
General & Administrative
Expenses |
$95.00 M
|
$35.18 M
|
$25.81 M
|
$13.27 M
|
$11.65 M
|
$11.05 M
|
$10.91 M
|
$7.91 M
|
$7.69 M
|
$7.03 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.67 M
|
$2.56 M
|
$717,000.00
|
Selling, General &
Administrative Expenses |
$95.00 M
|
$35.18 M
|
$25.81 M
|
$13.27 M
|
$11.65 M
|
$11.05 M
|
$10.91 M
|
$9.58 M
|
$10.25 M
|
$7.75 M
|
Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$69.86 M |
$0.00 |
$0.00 |
$0.00 |
$2.83 M |
$0.00 |
$0.00 |
Operating Expenses |
$254.76 M |
$136.08 M |
$82.69 M |
$41.57 M |
$46.44 M |
$41.47 M |
$30.54 M |
$10.46 M |
$11.25 M |
$8.04 M |
Cost And Expenses |
$254.76 M |
$136.08 M |
$82.69 M |
$41.57 M |
$46.44 M |
$41.47 M |
$30.54 M |
$13.01 M |
$13.73 M |
$11.29 M |
Interest Income |
$18.56 M |
$4.92 M |
$318,000.00 |
$173,000.00 |
$941,000.00 |
$1.25 M |
$403,000.00 |
$0.00 |
$0.00 |
$0.00 |
Interest Expense |
$1.85 M |
$486,000.00 |
$3,000.00 |
$508,000.00 |
$835,000.00 |
$873,000.00 |
$383,000.00 |
$95,000.00 |
$141,000.00 |
$1.02 M |
Depreciation &
Amortization |
$522,000.00
|
$755,000.00
|
$620,000.00
|
$539,000.00
|
$288,000.00
|
$281,000.00
|
$308,000.00
|
$341,000.00
|
$184,000.00
|
$144,000.00
|
EBITDA |
-$234.57 M
|
-$128.63 M
|
-$78.79 M
|
-$109.67 M
|
-$40.75 M
|
-$31.55 M
|
-$25.82 M
|
-$12.51 M
|
-$11.00 M
|
-$6.72 M
|
EBITDA Ratio |
-747.02 |
-73.02 |
-26.76 |
-38.42 |
-9.2 |
-3.8 |
-6.53 |
-2.84 |
-4.34 |
-1.58 |
Operating Income Ratio
|
-810.35
|
-75.79
|
-26.91
|
-105.12
|
-9.41
|
-3.95
|
-6.63
|
-3.75
|
-4.41
|
-1.59
|
Total Other
Income/Expenses Net |
$16.72 M
|
$4.43 M
|
$315,000.00
|
-$335,000.00
|
$106,000.00
|
$381,000.00
|
$20,000.00
|
-$166,000.00
|
-$141,000.00
|
-$1.02 M
|
Income Before Tax |
-$237.73 M |
-$129.87 M |
-$79.41 M |
-$110.72 M |
-$41.87 M |
-$32.70 M |
-$26.51 M |
-$12.67 M |
-$11.33 M |
-$7.89 M |
Income Before Tax Ratio
|
-757.11
|
-73.29
|
-26.8
|
-105.44
|
-9.39
|
-3.9
|
-6.62
|
-3.8
|
-4.46
|
-1.83
|
Income Tax Expense |
$0.00 |
-$4.43 M |
$3,000.00 |
$269,000.00 |
$547,000.00 |
$1.25 M |
$95,000.00 |
$95,000.00 |
$0.00 |
$1.02 M |
Net Income |
-$237.73 M |
-$125.44 M |
-$79.42 M |
-$110.98 M |
-$42.42 M |
-$32.70 M |
-$26.51 M |
-$12.67 M |
-$11.33 M |
-$7.89 M |
Net Income Ratio |
-757.11 |
-70.79 |
-26.8 |
-105.7 |
-9.51 |
-3.9 |
-6.62 |
-3.8 |
-4.46 |
-1.83 |
EPS |
-5.31 |
-3.91 |
-6.66 |
-31.2 |
-20.31 |
-16.57 |
-20.66 |
-17.57 |
-21 |
-52.46 |
EPS Diluted |
-5.31 |
-3.91 |
-6.66 |
-31.2 |
-20.31 |
-16.57 |
-20.66 |
-17.57 |
-21 |
-52.46 |
Weighted Average Shares
Out |
$44.76 M
|
$32.09 M
|
$11.92 M
|
$3.56 M
|
$2.09 M
|
$1.97 M
|
$1.28 M
|
$721,410.00
|
$539,445.00
|
$150,390.00
|
Weighted Average Shares
Out Diluted |
$44.76 M
|
$32.09 M
|
$11.92 M
|
$3.56 M
|
$2.09 M
|
$1.97 M
|
$1.28 M
|
$721,410.00
|
$539,460.00
|
$150,390.00
|
Link |
|
|
|
|
|
|
|
|
|
|